Frontiers in Clinical Drug Research - Anti-Cancer Agents Volume: 3
Nonfiction, Science & Nature, Science, Chemistry, Clinical
| Author: | Atta-ur-Rahman | ISBN: | 9781681082899 |
| Publisher: | Bentham Science Publishers | Publication: | May 30, 2016 |
| Imprint: | Language: | English |
| Author: | Atta-ur-Rahman |
| ISBN: | 9781681082899 |
| Publisher: | Bentham Science Publishers |
| Publication: | May 30, 2016 |
| Imprint: | |
| Language: | English |
Frontiers in Clinical Drug Research - Anti-Cancer Agents is an eBook series intended for pharmaceutical scientists, postgraduate students and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research. Reviews in each volume are written by experts in medical oncology and clinical trials research and compile the latest information available on special topics of interest to oncology researchers. The third volume of the eBook series begins with a detailed review of the molecular biology of inhibitors that target EGF-family receptors. This review is divided into two parts that covers extracellular and intracellular molecules. Other reviews cover targeted therapies for cancers such as melanoma, follicular lymphoma and topics such as cancer immunotherapy, apoptosis targeting and the Warburg Effect.
Frontiers in Clinical Drug Research - Anti-Cancer Agents is an eBook series intended for pharmaceutical scientists, postgraduate students and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research. Reviews in each volume are written by experts in medical oncology and clinical trials research and compile the latest information available on special topics of interest to oncology researchers. The third volume of the eBook series begins with a detailed review of the molecular biology of inhibitors that target EGF-family receptors. This review is divided into two parts that covers extracellular and intracellular molecules. Other reviews cover targeted therapies for cancers such as melanoma, follicular lymphoma and topics such as cancer immunotherapy, apoptosis targeting and the Warburg Effect.
